İçeriğe geç
akaturk Akademik ölçüm
Giriş Kayıt

Akademisyen

HAYRANİ EREN BOSTANCI

DOÇENT

SİVAS CUMHURİYET ÜNİVERSİTESİ ECZACILIK FAKÜLTESİ TEMEL ECZACILIK BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Eczacılık Biyokimyası

Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.

  • Makale 45
  • Proje 2
  • Kitap 8
  • Bildiri 17
  • Patent 0
  • Sanatsal 0
Scopus (SJR) Q1 19 Q2 40 Q3 16 Q4 3
WoS (JCR) Q1 11 Q2 42 Q3 21 Q4 4
TR Index 8 makale

Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.

Üst %1 makale 0
Üst %10 makale 13
Ort. yüzdelik 68.2%
Üst %1 payı 0.0%
Üst %10 payı 28.9%

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Dizin filtreleri

Toplam 45 yayın

Scopus (SJR)
Q1 19 Q2 40 Q3 16 Q4 3
WoS (JCR)
Q1 11 Q2 42 Q3 21 Q4 4
TR Index
8 makale

Makale listesi

  1. 2026 Design, Synthesis and Molecular Modeling Studies of Triazole Derivatives as Aromatase İnhibitors Chemical Biology & Drug Design DOI 10.1111/cbdd.70322 YÖKSİS SJR Q2 JCR Q3 OpenAlex 48.3%
  2. 2026 Synthesis of Novel Benzimidazole Derivatives as a Carbonic Anhydrase IX (Ca IX) Inhibitor With Anticancer Potential JOURNAL OF HETEROCYCLIC CHEMISTRY DOI 10.1002/jhet.70138 YÖKSİS SJR Q3 JCR Q2 OpenAlex 21.3%
  3. 2026 Conformationally adaptive benzimidazolium–chalcone hybrid salts as selective TGF-β1 inhibitors Bioorganic Chemistry DOI 10.1016/j.bioorg.2026.109911 YÖKSİS SJR Q1 JCR Q1 OpenAlex 34.2%
  4. 2026 New Antiproliferative Pyrazole/Quinoline Hybrids: Design, Synthesis, and Biological Evaluation as EGFR Inhibitors Chemical Biology & Drug Design DOI 10.1111/cbdd.70256 YÖKSİS SJR Q2 JCR Q3 OpenAlex 89.1%
  5. 2026 A novel platinum(II) complex bearing 6,6′-Bis(N-Methylbenzimidazol-2-yl)-2,2′-bipyridine: Synthesis, characterization, and anticancer activity Journal of Molecular Structure DOI 10.1016/j.molstruc.2026.146078 YÖKSİS SJR Q2 JCR Q2 OpenAlex üst %10 OpenAlex 92.5%
  6. 2026 Apoptosis-Inducing Antitumor Activity of Curcumin-Loaded PCL Microfibers Incorporating Nano-Hydroxyapatite for Breast Cancer Therapy ACS Omega DOI 10.1021/acsomega.5c10882 YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 95.9%
  7. 2026 Investigation of Carbonic Anhydrase Inhibition, Antioxidant Properties, and Selective Anticancer Activity of Methyl‐Substituted Halogenated and Methoxy Conduritols BioMed Research International DOI 10.1155/bmri/5819417 YÖKSİS SJR Q2 JCR Q3 OpenAlex 85.8%
  8. 2025 Green Synthesis and Characterization of Silver and Zinc Nanoparticles Using Pyracantha coccinea M. Roem and Their Biological Activities Applied Organometallic Chemistry DOI 10.1002/aoc.70391 YÖKSİS SJR Q2 JCR Q1 OpenAlex 47.3%
  9. 2025 Synthesis, antibacterial, anti-urease, DFT and molecular docking studies of novel bis-1,3,4-thiadiazoles Journal of Molecular Structure DOI 10.1016/j.molstruc.2024.140134 YÖKSİS SJR Q2 JCR Q2 OpenAlex 52.2%
  10. 2025 Synthesis and anti-cancer properties of Pd(II) and Pt(II) coordination compounds of heterocyclic Schiff base ligands Journal of Molecular Structure DOI 10.1016/j.molstruc.2025.142199 YÖKSİS SJR Q2 JCR Q2 OpenAlex 88.8%
  11. 2025 Benzothiazole-thiadiazole hybrids as dual α-glucosidase and aldose reductase inhibitors: Synthesis, in vitro, and In Silico studies JOURNAL OF MOLECULAR STRUCTURE DOI 10.1016/j.molstruc.2025.144995 YÖKSİS SJR Q2 JCR Q2 OpenAlex 28.2%
  12. 2025 Synthesis, characterization, antimicrobial, antioxidant, and anti-cancer activity of new hybrid structures based on benzimidazole and thiadiazole Brazilian Journal of Pharmaceutical Sciences DOI 10.1590/s2175-97902025e23939 YÖKSİS SJR Q3 JCR Q4 OpenAlex 60.0%
  13. 2025 New benzimidazole derivatives containing hydrazone group as anticancer agents: Inhibition of carbonic anhydrase IX and molecular docking studies Archiv Der Pharmazie DOI 10.1002/ardp.202400930 YÖKSİS SJR Q2 JCR Q2 OpenAlex 89.3%
  14. 2025 Novel Benzimidazole–Oxadiazole Derivatives as Anticancer Agents with VEGFR2 Inhibitory Activity: Design, Synthesis, In Vitro Anticancer Evaluation, and In Silico Studies ACS Omega DOI 10.1021/acsomega.4c08885 YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 97.7%
  15. 2025 Design, Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 1,3,4-Thiadiazole Derivatives Targeting Both Aldose Reductase and α-Glucosidase for Diabetes Mellitus ACS Omega DOI 10.1021/acsomega.5c00566 YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 92.0%
  16. 2025 New hydrazone derivatives: synthesis, characterization, carbonic anhydrase I-II enzyme inhibition, anticancer activity and in silico studies Zeitschrift für Naturforschung C DOI 10.1515/znc-2024-0226 YÖKSİS SJR Q3 JCR Q3 OpenAlex 87.5%
  17. 2025 Synthesis and in silico study of novel benzimidazole derivatives bearing oxadiazole moiety as potential carbonic anhydrase inhibitors, anticancer and antioxidant agents Journal of Molecular Structure DOI 10.1016/j.molstruc.2025.142750 YÖKSİS SJR Q2 JCR Q2 OpenAlex 85.4%
  18. 2025 Synthesis of Novel Benzimidazole Derivatives as a Carbonic Anhydrase IX (Ca IX) Inhibitor With Anticancer Potential JOURNAL OF HETEROCYCLIC CHEMISTRY DOI 10.1002/jhet.70138 YÖKSİS SJR Q3 JCR Q2 OpenAlex 21.3%
  19. 2024 Synthesis and Characterization of Oxime Derivatives and their Some Transition Metal Complexes with Thiadiazole Groups: Biological Activities, and Molecular Docking Studies of the Ligands ChemistrySelect DOI 10.1002/slct.202400863 YÖKSİS SJR Q3 JCR Q3 OpenAlex 67.6%
  20. 2024 New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study Drug Development Research DOI 10.1002/ddr.22218 YÖKSİS SJR Q2 JCR Q1 OpenAlex üst %10 OpenAlex 93.0%

Akademisyenlere dön